AIM ImmunoTech Updates Corporate Address in 8-K Filing
Ticker: AIM · Form: 8-K · Filed: Jan 25, 2024 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-update, regulation-fd
TL;DR
**AIM ImmunoTech filed a routine 8-K updating its address, no big news here.**
AI Summary
AIM ImmunoTech Inc. filed an 8-K on January 25, 2024, primarily to update its corporate address to 2117 SW Highway 484, Ocala, FL 34473, and confirm its telephone number as (352) 448-7797. This filing, under Regulation FD Disclosure, also re-affirms its status as a non-emerging growth company. For investors, this administrative update signals stability in corporate operations but offers no new financial or strategic information that would directly impact stock valuation.
Why It Matters
This filing is largely administrative, updating contact information. It doesn't contain new financial results, strategic announcements, or material events that would typically move the stock price.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or strategic risks to the company.
Analyst Insight
Smart investors would recognize this as a routine administrative filing with no material impact on the company's fundamentals or stock price, and thus no immediate action is warranted based solely on this 8-K.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — the registrant filing the 8-K
- 2117 SW Highway 484, Ocala, FL 34473 (address) — the updated principal executive offices address
- (352) 448-7797 (phone_number) — the registrant's telephone number
- January 25, 2024 (date) — the date of the report
FAQ
What is the primary purpose of AIM ImmunoTech Inc.'s 8-K filing dated January 25, 2024?
The primary purpose of the 8-K filing is to update the company's principal executive offices address to 2117 SW Highway 484, Ocala, FL 34473, and confirm its telephone number as (352) 448-7797, as indicated under 'ITEM INFORMATION: Regulation FD Disclosure'.
What is AIM ImmunoTech Inc.'s current business address and phone number as stated in this filing?
According to the filing, AIM ImmunoTech Inc.'s current business address is 2117 SW Highway 484, Ocala, FL 34473, and its telephone number is (352) 448-7797.
Is AIM ImmunoTech Inc. classified as an 'emerging growth company' based on this 8-K?
No, the filing indicates with an unchecked box next to 'Emerging growth company' that AIM ImmunoTech Inc. is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Under which items of Form 8-K was this report filed?
This report was filed under 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.
What was the former name of AIM ImmunoTech Inc. and when did the name change occur?
The former name of AIM ImmunoTech Inc. was HEMISPHERX BIOPHARMA INC, and the date of the name change was 19950614 (June 14, 1995), as stated in the 'FORMER COMPANY' section of the filing.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-25 17:00:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 447KB
- ex99-1_002.jpg (GRAPHIC) — 575KB
- ex99-1_003.jpg (GRAPHIC) — 294KB
- ex99-1_004.jpg (GRAPHIC) — 250KB
- ex99-1_005.jpg (GRAPHIC) — 283KB
- ex99-1_006.jpg (GRAPHIC) — 285KB
- 0001493152-24-003779.txt ( ) — 3154KB
- aim-20240125.xsd (EX-101.SCH) — 3KB
- aim-20240125_lab.xml (EX-101.LAB) — 33KB
- aim-20240125_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM IMMUNOTECH INC. January 25, 2024 By: /s/ Thomas K. Equels